Undeterred by Cerevel's Setback, AbbVie Acquires Gilgamesh’s Depression Treatment for $1.2 Billion

Undeterred by Cerevel’s Setback, AbbVie Acquires Gilgamesh’s Depression Treatment for $1.2 Billion